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Introduction 
 
Disease 
 
Pigeon fever, or dryland distemper, is a disease caused by the bacterium Corynebacterium 
pseudotuberculosis. As one of the “most common and economically important infectious diseases of 
horses,” it is very common in young adult horses and in warmer climates, becoming widespread in 
California, Arizona, and other states. Peak infection is during late summer and fall (Doherr, et al. 1998). 
Songer et al. found two main biovars of the bacteria: equi and ovis, by studying bacterial isolates from 
different animal species. While all the isolates contained phospholipase D, isolates in horses were able 
to reduce nitrates, unlike isolates from sheep and goats. This key difference is used to differentiate 
between the ovis and equi biovars of the bacteria. 
 
Pigeon fever, named for characteristic pectoral swelling, refers to the disease manifestation in 
horses caused by the bacteria; in small ruminants, the disease is known as caseous lymphandenitis. 
Pigeon fever can manifest in one or more of three forms: external abscesses, internal infections, and 
ulcerative lymphangitis, with external being the most common form of the disease (Spier 2006). 
Figure 2: Horse with external abscess 
http://www.wildhorsefoundation.org/pigeon%20fever.htm 
Figure 2: Horse with multiple abscesses (red arrows) 
http://eliteequineks.com/wp-content/uploads/2012/11/Elite-
Equine-Vet-Kansas-Pigeon-Fever.jpg 
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Compared to the external form where horses commonly exhibit non-healing wounds, fever, and edema, 
internal abscesses are particularly difficult to diagnose because of non-specific symptoms such as fever 
and weight loss (Aleman, et al. 1996). It is not currently known what influences which form of the 
disease occurs. Incidence of disease does not correlate with age, breed, or sex of the horse (Spier 2006). 
Because diagnostic techniques and veterinary treatment are not completely effective, the disease is 
difficult to identify and treat. The bacteria are protected within the thick capsules of the abscesses, 
limiting the effectiveness of antibiotics (Dorella, et al. 2006). General strategies for addressing a 
breakout of the disease within a herd include limiting its spread by quarantining infected animals. 
Sanitation is essential by disposing of contaminated bedding, not using the same tools for healthy and 
infected horses, and ensuring that open wounds are kept clean and heal quickly (Thomas 2009). 
Interestingly, there have been twelve reported cases where the disease has been contagious to human 
beings. Nine of these twelve have been in Australia, predominantly among farm workers or with open 
wounds that came in contact with infected animals (Peel, et al. 1996).  
Bacteria 
 
Corynebacterium pseudotuberculosis is a gram-positive facultative anaerobe bacterium that 
causes pigeon fever in horses and caseous lymphandenitis in ruminants such as cows and goats (Nieto, 
et al. 2009). The bacterium is a close relative to C. diptheriae and C. ulcerans, (Songer, Beckenbach, et al. 
1988). First isolated from bovine samples in 1988, it exists in pleomorphic forms including filamentous 
rods and coccoids, but is non-motile, non-sporulating, and non-capsulated (Dorella, et al. 2006). The 
bacterium secretes multiple exotoxins, among which phospholipase D (PLD) is the major one and the 
most studied. These molecules are able to hydrolyze ester bonds in glycerophospholipids which 
damages cell membranes and contributes to spread of the disease (Spier, 2006).  
Infection seems to happen by entry through wounds and skin abrasions in addition to through 
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mucus membranes and is believed to be spread by insect vectors including house flies and other diptera 
(Aleman, et al. 1996). Research on insects present around infected horses has shown that the bacteria 
are present in the insects, especially the house fly, horn fly, and stable fly. This is interesting considering 
that horn flies feed along the ventral midline of the horses, where most infections start (Thomas 2009). 
When the bacterium enters the organism, macrophages and neutrophils phagocytose the bacteria as a 
means of defense. However, it is able to survive within these cells and spread throughout the body 
within the blood and lymph. As the bacteria continue to replicate within the phagocytic cell, the host cell 
eventually dies, facilitating further pathogenesis (McNamara, Bradley and Songer 1994). 
There are two main characteristics that make the bacteria particularly suited for infection: the 
cell wall’s high lipid content that helps the bacteria to survive inside macrophages and the bacteria’s 
secretion of exotoxins (Aleman, et al. 1996). The bacteria are susceptible to most antimicrobials 
including ampicillin, lincomysin, tetracycline, and others. However, researchers found that a few strains 
of bacteria are resistant to neomycin and all are resistant to streptomycin (Dorella, et al. 2006). In an 
effort made to reproduce natural conditions of infection, researchers grew the bacteria in a biofilm and 
found that the bacteria were highly resistant to all the drugs that were administered (Olson, et al. 2002).  
Phospholipase-D 
Phospholipase-D (PLD) is the main exotoxin produced by both the C. pseudotuberculosis and C. 
Figure 3: Sites of Phospholipase Activity 
http://www.bioscience.org/1998/v3/d/roldan/fig1
.jpg 
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ulcerans species (Barksdale, et al. 1981). It was detected at early stages of research as a protein with a 
weight of about 31 kDa in Corynebacterium that was bound by sera antibodies of an infected sheep 
(Songer, Libby, et al. 1990) (Hodgson, Bird and Nisbet, Cloning, Nucleotide Sequence, and Expression in 
Escherichia coli of the Phospholipase D Gene from Corynebacterium pseudotuberculosis 1990). PLD 
forms dermonecrotic lesions and even death when introduced in different laboratory animals. The use 
of an antitoxin has been applied to stop the spread of the disease; however it is unable to prevent 
abscess formation (Dorella, et al. 2006). PLD acts by inhibiting neutrophil chemotaxis and degranulation 
of phagocytic cells and hydrolyzing phosphatidylcholine and sphingomyelin to increase vascular 
permeability (see figure 3), contributing to disease pathogenesis (Aleman, et al. 1996). Using protection 
studies, laboratories have shown that PLD is crucial for the spread of the bacteria within the host 
(McNamara, Cuevas and Songer, Toxic phospholipases D of Corynebacterium pseudotuberculosis, C. 
ulcerans and Arcanobacterium haemolyticum: cloning and sequence homology 1995).  
To characterize the protein, multiple efforts have been made to clone and sequence the gene 
using Escherichia coli such as those done by Songer et al, McNamara et al, and Hodgson et al. Songer et 
al found that the two biovars of C. pseudotuberculosis differ not only in nitrate reduction activity or 
response to streptomycin, but also by restriction length polymorphisms in Southern blots (Songer, Libby, 
et al. 1990).  
Immunology 
 
 The mammalian immune system must be understood in order to understand the aims of this 
research project. First, the immune response is divided into two subsets: the humoral and cell-mediated 
responses (figure 5). The humoral response primarily involves the formation of B lymphocytes which 
differentiate into plasma cells (that secrete antibodies) and memory B cells following exposure to a 
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specific antigen. Humoral immunity specifically involves the role of antibodies and complement proteins 
to mediate and direct the immune response.  
 On the other hand, the cell-mediated immune response deals with the role of cell to cell 
interactions including killing of infected cells by cytotoxic T-cells. Upon exposure to an antigen, T-cells 
differentiate into Tc (cytotoxic) cells and TH (helper) cells. TH cells are able to further differentiate into 
two subsets: TH1 and TH2 cells, both with different profiles of cytokine secretion (figure 4). Our lab has 
hypothesized that, generally, external abscesses are only able to form if the immune response is skewed 
towards a TH1 response, while the sometimes fatal internal abscesses are allowed by a TH2 skewed 
response. This theory is modeled after leprosy, a disease also caused by an intracellular pathogen. The 
two forms of leprosy: tuberculoid leprosy and lepromatous leprosy depend on the immune response of 
the host. A TH1 response results in tuberculoid leprosy, forming granulomas. On the other hand, TH2 
response characterizes lepromatous leprosy, which leads to severe nerve and tissue damage (Kindt, 
Goldsby and Osborne 2007). By studying the cytokine responses of individual horses to an infection, we 
can attempt to determine if the various forms of pigeon fever are linked to the predominant TH subset, 
important information for a diagnostic assay. The cell-mediated response activates cells to phagocytize 
foreign antigens, induces apoptosis in infected cells, and prompts cytokine secretion.  
Figure 4: Lymphocyte activation (Rang and Dale 2003) 
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Figure 5: Cell-mediated and humoral responses of the mammalian immune system (Kindt, Goldsby and Osborne 2007) 
Research Project 
 
We hope to study the immune response to C. pseudotuberculosis in order to develop diagnostic 
tools and vaccines. Currently, we measure the humoral immune response through the extensive use of 
ELISAs (Enzyme-Linked Immunosorbent Assays) which measure antibody levels to bacterial proteins in 
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sera from infected and uninfected horses (Kindt, Goldsby and Osborne 2007). Identifying if disease type 
is correlated to a certain TH subset response or other factors would help develop a diagnostic assay. 
Furthermore, we hope in the long term to be able to promote the development of a commercial 
vaccine. Currently, there is a vaccine available for the sheep biovar of the bacteria, due to the danger 
the disease poses to sheep and other commercial farm animals. Released in 1983 in Australia and known 
as the Glanvac vaccine, it is multicomponent and contains an adjuvant (Peel, et al. 1996). This type of 
vaccine known as a toxoid vaccine, includes antigens of other bacteria and uses an inactivated version of 
PLD as one of its primary components (Dorella, et al. 2006). Eggleton et al studied whether the inclusion 
of antigens for multiple bacteria in the same vaccine has any impact on protective effects for caseous 
lymphandenitis. They found that when compared to mono-component vaccines using formalin-
inactivated PLD, multi-diseases vaccines had the same level of effectiveness (Eggleton, et al. 1991). The 
commercially available and widely used multicomponent vaccine has shown protective effects for 70-
90% of vaccinated sheep and goats (McNamara, Bradley and Songer 1994). The vaccine isn’t approved 
for use in horses. Because this formulation has proved to be highly effective in sheep, similar results 
should be expected from a horse variant as well (Pollock 2009). However, owners of companion animals 
will be less tolerant of side effects such as granulomas than owners of agricultural animals.  
My previous research in the lab has involved studying both branches of the immune system: 
humoral (production of antibodies) and cell-mediated (cells having various functions such as killing 
infected cells). ELISAs that I previously carried out measured the level of antibodies to PLD in horse 
serum samples. TH cells, or T-helper cells are one of the primary cell types involved in the immune 
system by prompting a response from both humoral as well as cell-mediated branches.  Some subclasses 
of antibody can indicate a TH1 or TH2 response. Both the TH cell types may have different responses 
depending on the form of pigeon fever occurring.  
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Research has shown that in the course of the disease, PLD-specific antibody responses have a 
protective effect in sheep and PLD-deficient or mutant PLD-producing C. pseudotuberculosis is unable to 
cause caseous lymphandenitis in sheep (Tachedjian, et al. 1995) (McNamara, Bradley and Songer 1994). 
As a result, my main project has focused on this protein and has involved purification of recombinant 
phospholipase-D, through growing bacteria that produce histidine-tagged wild type or mutant PLD, cell 
lysing via sonication, and purifying PLD from supernatant using a TALON column (Clontech Inc., 
Mountain View, CA). It has been important to optimize the yield of the purification process, in order to 
collect prep concentrations that exceed at least 500 µg/mL. The expression vector for producing wild 
type PLD in E. coli was made using the multiple cloning site of the PTrcHis plasmid and was a gift from 
Dr. Steve Billington from the University of Arizon at Tucson. When expressed, PLD is translated with a 5’ 
6xHis tag, allowing us to use affinity chromatography to purify the protein.  
I have been studying the various methods to inactivate PLD such as heat-denaturation, formalin-
crosslinking, and genetic mutation with the intent to identify new components for developing a vaccine. 
A paper by Tachedjian et al (1995) noted that commercially available vaccines depended on formalin-
inactivated PLD as the main antigen. They tested site-specific mutations at the PLD catalytic site and 
magnesium/calcium binding domain and found that one such mutation of site 20 (histidine), in the 
active site, to serine resulted in a 40% reduction in secretion, with minimal enzymatic activity 
(Tachedjian, et al. 1995). Previous research found that a mono-component sheep vaccine preparation 
using the mutant variety of PLD had only an effective disease protection rate of 44% compared to 95% 
for the multi-component formalin-inactivation preparation (Hodgson, Carter, et al. 1998). We hope that 
a vaccine with the mutation-inactivated PLD will be successful for horses as a more efficient and safe 
alternative to formalin-inactivation.  
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With the potential mutant PLD vaccine, we have started a mouse model using PLD to immunize 
mice. In addition to inactivated forms of PLD protein, we also used the mouse model to test a DNA 
vaccine, the mutant PLD sequence in a mammalian expression vector. Existing research has shown the 
potential of a DNA vaccine in sheep and we hope to replicate the results for the equi biovar (Chaplin, et 
al. 1999). The secretion of PLD by native immune cells would a natural antigen for eliciting an immune 
response and conferring protective effect through an increased cell-mediated response due to 
presentation on the multihistocompatability complex (MHC). Using the services of an external company, 
Nature Technology Corporation (Lincoln, NE), we had a mutated version of the PLD gene inserted into a 
plasmid vector that gets expressed in mammalian cells. Once this or other vaccine components such as 
the mutant protein  were injected into mice, we tracked the immune response using ELISA assays on 
sera collected at regular intervals. Currently we are carrying out a mouse model, with upcoming boosts 
and eventual bacterial challenge with live C. pseudotuberculosis this summer, to see if any of the various 
vaccines provide a protective effect.  
Materials and Methods 
PLD Purification 
PLD is harvested from DH5α E. coli transformed bacteria with a recombinant histidine-tagged 
PLD gene in multicloning site of the pTrcHis plasmid (a gift from Dr. Stephen Billington, University of 
Arizona, Tucson, AZ). We also used a company Genscript (Piscataway, NJ) to induce a site-specific 
mutation at site 20 of the protein; a histidine (CAC) was changed to serine (TCT). Our lab designed 
Streak E. coli 
containing 
recombinant 
PLD and grow 
in small 
culture 
overnight 
Transfer 
E. coli 
into large 
culture 
then add 
IPTG 
Spin to 
pellet 
bacteria 
and lyse 
using 
sonication 
Spin to 
collect 
cell lysate 
Bind to 
TALON 
residue 
Wash and 
elute 
through 
TALON 
cobalt 
column 
Dialyze to 
remove 
imidazole 
or EDTA 
Figure 6: Purification process 
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Wild type PLD sequence: 5’ CTATGCGATTGCCCACCGCGTTTTAACCAC 3’ 
                    (His 20) 
     Mutant PLD sequence: 5’ CTATGCGATTGCCTCTCGCGTTTTAACCAC 3’ 
                     (Ser 20) 
sequence primers so that we could ensure that the full PLD sequence was included within the 
multicloning site of pTrcHis.  We also included two primers complementary to the pTrcHis sequence, 
one on each side of the PLD insert so we could confirm that the insert was in the correct 
orientation. Sequencing was completed by Genscript and we were sent mutant plasmid sequencing 
information to ensure that the desired change was complete. As with the wild type PLD, the mutant 
version of the protein is harvested from transformed DH5α E. coli.  
We grew the transformed bacteria containing the wild type or mutant 6xHis tagged PTrcHis 
(strand JG52274). The culture plates were then left overnight at 37°C. An isolated colony was then 
picked and cultured in 3 mL of LB+AMP 
overnight. The culture was then added to 
500 mL of LB+AMP for ~24 hours in the 
warm room. Following the time period, we 
took a sample and read the OD600 of the 
culture to ensure it is above 0.6 absorbance. 
If it is, we add 2.5 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) to induce PLD 
expression and leave the flask to shake at 
37°C for three hours. 
During the process of yield optimization, we changed the protocol. The following are the steps 
with which our PLD was isolated and purified. Following culturing, the culture was then removed from 
the warm room and transferred from the 2 L flask to two plastic centrifuge bottles. Cells were harvested 
Figure 7: pTrcHis Plasmid 
http://tools.invitrogen.com/content/sfs/manuals/ptrchis_man.pdf 
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by centrifuging at 7000 xg for 15 minutes. The supernatant is then discarded. We then resuspended the 
pellet with 10 mL of binding buffer. Once the pellet in that centrifuge bottle was resuspended, we 
transferred the solution to the other centrifuge bottle and resuspended the pellet from the second 
plastic bottle. We transferred the resuspended pellets to a 50 mL conical tube and filled it with binding 
buffer until it reached 35 mL of volume. Cells were sonicated (50% duty cycle, output of six) three times 
at four minute intervals. Sonicated cells were transferred to two polycarbonate tubes, after we made 
sure each tube has the same volume with up to 0.2 g difference. The polycarbonate tubes were spun for 
20 minutes at 15,000 x g at 4°C. Supernatant was collected in a 50 mL conical and we discarded the 
pellet. The PLD is in the supernatant. 
 PLD was isolated using a cobalt metal affinity column. Using a plastic flow column and TALON 
metal affinity resin seen in figure 8 (Clontech Inc., Mountain View, CA), we set up the chromatography. 
We washed the columnp five times with 8 mL of MES buffer and then once with 8 mL of binding buffer. 
We capped the column and added binding buffer, resuspending and transferring to 50 mL conical tube. 
It was spun at 700 xg for 1-2 minutes at 4°C. We then discarded the supernatant and repeated. The resin 
was shaken with the PLD supernatant gently for 20 minutes in the cold room at 4°C. We centrifuged 
again for 2 minutes at 700 xg and discard supernatant. We then added binding buffer to PLD and resin. It 
was shaken gently at 4°C for 10 minutes, then spun and the supernatant was discarded. Next step was 
Figure 8: Illustration of Clontech’s TALONTM Metal Affinity system. 
A: BD TALON Cobalt affinity resin consisting of cobalt chelator ion bound to sepharose bead. 
B: 6x histidine tagged PLD binds to the Co2+ 
Source: BD TalonTM Resin User Manual, Clontech (Mountain View, CA) 
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to add 8 mL of binding buffer and transfer back to column, discard flow through and repeat. We then 
soaked with 10 mM wash buffer for 8-10 minutes, discarding the flow through and repeating two more 
times. We added 2 mL of elution buffer (appendix) and let it settle for 8-10 minutes.  We collected the 
PLD in 1 mL tube and stored resin at 4°C. This is the concentrated but not purified PLD. 
The newer version of the protocol used for the last few PLD samples is described here. Following 
culturing, cells were harvested by centrifuging at 7000 xg for 15 minutes as before. We then 
resuspended the pellet with 10 mL of equilibrium buffer. Once the pellet was resuspended, we added 
equilibrium buffer to a total volume of 35 mL. Cells were sonicated three times at 50% intensity for 10 
seconds, with 0.5 seconds on/off. Sample was cooled on ice for 30 seconds in between sonication cycles. 
Sonicated cells were spun for 20 minutes at 10,500 RPM in a Beckman JA-17 rotor at 4°C. Supernatant 
was collected in a 50 mL conical and we discarded the pellet. At this stage, the PLD is in the supernatant. 
 The next part involved extracting the PLD using a cobalt metal affinity column. Using a plastic 
flow column and TALON metal affinity resin, we set up the chromatography. We used 4 ml of resin slurry 
(2 ml bed volume). We centrifuged the slurry to pellet the resin and discarded the supernatant. 
Following this, we rinsed the resin twice with equilibrium buffer and spun to pellet once again. Following 
this, we added the clarified cell lysate to the resin. The mixture was then left on a vertical tube rotator 
for 20 minutes at 4°C. Using 700 xg centrifugation for 2 minutes, the components were then separated 
and the supernatant was discarded. We then rinsed the resin of unbound materials 2-3 times using 
successive equilibrium buffer washes and centrifugation of the same duration. The final resin/buffer 
slurry was then transferred to a ClontechTM (Mountain View, CA) gravity flow column and the resin was 
allowed to settle out of suspension. After a final rinse, we carried out one or two washes with 
equilibrium buffer with 10 mM of imidazole to remove weakly bound particles. Finally, for the first 
elution we used 2 mL of 150 mM elution buffer which we allowed to flow through. For the second 
Patwardhan Honors Thesis 16 
 
elution, we used a 100mM EDTA elution buffer which we allowed to soak the resin for 30 minutes. Flow 
through was collected.  
 The final step involves using the Slide-A-Lyzer dialysis cassette (ThermoScientific, Vernon Hills, 
IL). We immersed the cassette in dialysis buffer (1X phosphate-buffered saline at pH 7) for two minutes 
to moisten the membrane. After using a syringe to load in the PLD, we then spun the cassette in dialysis 
buffer at 4°C for 72 hours, replacing with new buffer every 24 hours. We then removed the cassette 
from the buffer. After dialysis, PLD was stored in a freezing vial in -20°C freezer. This was followed up 
with a bicinchoninic (BCA) assay (Thermo Fisher Scientific, Rockford, IL) to determine protein 
concentration. 
Formalin-Inactivation 
 
 For every 1 mL of concentrated PLD solution, we used 40 µL of 10% buffered formalin. The 
resulting solution was left for 72 hours at 37°C on a rocker. Following inactivation, formalin was dialyzed 
out using dialysis tubing or a dialysis cassette in a 1x PBS solution for 24 hours at 4°C. PBS solution was 
changed 3-5 times. During formalin-inactivation, PLD tends to precipitate out, so it’s important that any 
solid matter is re-suspended. Testing of final concentration is also done using a BCA assay.  
BCA Assay 
 
 The bicinchoninic acid assay (BCA assay) determines the total level of protein in a sample. The 
measurement is calculated by the degree of color change of the sample from green to purple. We used 
an array of standards including 2000, 1000, 500, 250, 125, 62.5, 31.25, and 0 µg/mL of bovine serum 
albumin. Using a 96-well plate, we added 25 µL of each BSA standard and unknown in triplicates. 200 µL 
of working reagent was added to each sample well, with a 50:1 ratio of substrates A and B from the 
ThermoFischerScientific (Rockford, IL) Pierce BCA Protein Assay kit. We agitated the plate for 30 seconds. 
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It was then incubated for 30 minutes at 37°C. Finally, we measured the OD570 reading on a Biorad 
Benchmark Microplate Reader (Hercules, CA). Protein concentration was determined using a best fit 
polynomial curve for the standards.  
Sodium Dodecyl Sulfate-Poly Acrylamide Gel Electrophoresis (SDS-PAGE) 
 
 Sodium dodecyl sulfate polyacrylamide gel electrophoresis, SDS-PAGE, is a technique used to 
fractionate proteins by size. The protocol begins with opening a 4-15% poly-acrylamide gradient Tris-HCl 
gel. We prepared 800 mL of of 1X running buffer (appendix) for the SDS-PAGE apparatus. The protein 
samples are heated in a 94°C heat block for about five minutes. We then loaded 15 µL of the 
kaleidoscope marker and 20 µL aliquots of the samples into wells. The gel was run at 200 volts for about 
40 minutes, ensuring that the dye reaches the end of the gel. The gel was rinsed in ddH2O.  Then it was 
washed in ddH2O three times for five minutes each, with shaking. We washed in Bio-Safe coomassie 
(Bio-Rad Laboratories, Hercules, CA) for one hour, with shaking. Lastly, the gels were washed with water 
for five minutes and then photographed. 
Western Blot 
 
 To run a Western blot, we would run a duplicate to the SDS-PAGE gel being used for coomassie 
staining. Following completion of electrophoresis, we prepared the nitrocellulose membrane 
“sandwich” by layering wet membrane with Whatmann paper, sponge pads, and the gel to transfer. We 
ran the apparatus at 12 V overnight with a stir bar maintaining circulation. After completion, membrane 
was rinsed with ddH20 and then immersed in blocking buffer (5% nonfat dry milk in TBST) for an hour. 
After a brief rinse with ddH20, we incubated the membrane for one hour in the primary antibody with 
binding buffer (appendix). After three washes with 150 mM tris-buffered saline 0.1% tween 20 (TBST), 
we added the secondary antibody diluted in blocking buffer and agitated on the shaker for one hour. 
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After two washes in TBST and one wash in just TBS (tris-buffered saline) for 15 minutes, we added the 
Opti-4CN (Bio-Rad, Hercules, CA) working reagent (substrate, diluent, and ddH20) and incubated until 
lane darkness was adequate. After a brief rinse with ddH20, we photographed and dried the membrane.  
Bacterial Transformation 
 
The bacteria were transformed to contain the plasmid with ampicillin resistance and the PLD 
insert. To start off, the 50 µL of competent cells was incubated on ice for 30 minutes after adding 5 µL of 
the ligation mix product (appendix). Then, the cells were incubated in ice for 30 minutes. The cells were 
then heat-shocked at 42°C for 20 seconds to increase permeability. The tube was placed on ice for 2 
minutes following which 950 µL of super optimal broth with catabolite repression (SOC medium) was 
added to facilitate adaptation of the bacteria to glucose as its energy source. The tube was then 
incubated at 37°C with shaking for an hour. The two LB agar + ampicillin (LBA) plates were labeled “100 
µL” and “900 µL.” The tube was flicked to mix the cells. The plates were spread with 100 µL of the cells. 
Then, the remaining bacteria were concentrated by transferring bacteria to a microfuge tube and 
spinning bacteria down for about 5 seconds in the microfuge. Then, the bacterial pellet was 
resuspended by finger flicking and then gently pipetted. These were then plated onto the plate labeled 
“900 µL.” The plates sat at room temperature for few minutes to air dry and we then put into the warm 
room upside-down overnight. 
Once the plates were removed from the refrigerator, four culture tubes were set up with 
1.8mL/tube of LB-AMP. By using the wire loop, a white colony was picked and placed into each tube. 
Two of the four colonies came from the “100 µL” plates, and other two came from “900 µL” plates. The 
tubes were placed in the 37°C shaker for 12-16 hours. The LB + AMP with the bacteria was transferred in 
to four separate 1.5mL Eppendorf tubes and stored at 4°C. 
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Mini-preps 
 
Minipreps were carried out with the QIAprep Spin Miniprep Kit (Qiagen, Venlo, Netherlands). 
The culture tube was centrifuged at 2200 x g for 2 minutes to pellet the cells. The supernatant was 
discarded. The cell pellet was resuspended in 250 µL of Qiagen buffer P1. Then, 250 µL Qiagen buffer P2 
was added and the solution was mixed gently by inverting the tube 5 to 6 times. Then, 350 µL of Qiagen 
buffer N3 was added and mixed by inverting the tube again 5-6 times. The tube was placed in the 
microfuge and spun at 16,000x g for 10 minutes to pellet the cell debris. The supernatant then was 
transferred into a Qiaprep column. 
The column was placed in a 1.5 mL collection tube and centrifuged at 10,000x g for a minute. 
Flow through was then discarded. We then added 750 μL of Qiagen buffer PE to the column and it was 
centrifuged at 10,000x g for one minute, following which the flow through was discarded once again. 
The column was then centrifuged to remove liquids. Lastly, 50 μL of Qiagen buffer EB (10mM Tris, pH 
8.5) was added to the top of the column and spun at 10,000x g in a microfuge for one minute. 
Restriction Enzyme Digests 
 
 The restriction enzyme digests of the mutated PLD DNA were set up: 7.0 µL of sterile H2O, 2 µL 
of 10X EcoRI restriction buffer, 10 µL of mutant PLD product, and 1 µL of EcoRI restriction enzyme were 
added into the “EcoRI digest” tube. For the double digest, we used PvuI as the second restriction 
enzyme. The digest tube was flicked and spun briefly in the microfuge and placed in the 37°C incubator. 
The digest was incubated overnight for approximately 16 hours. Then, the digest was stored at -20°C. 
Agarose Gel Electrophoresis 
After preparing the mutant PLD restriction digests, we prepared the gel for electrophoresis of 
the DNA samples. We added 8 µL (20% of reaction volume) of 10X loading buffer. We added ethidium 
Patwardhan Honors Thesis 20 
 
bromide solution (0.5 mg/mL) to each sample for a final concentration of 0.5 µg/mL, as well as 1.0 g of 
electrophoresis grade agarose to a 100 mL volume of electrophoresis buffer to make 1% agarose gel. 
The agarose was melted in a bottle with the cap loosely on in a microwave oven and swirled to ensure 
even mixing. We then sealed the gel-casting platform with tape.  We poured in the melted agarose and 
inserted the gel come, making sure that no bubbles are trapped underneath the combs and all bubbles 
on the surface of the agarose were removed before the gel sets. 
After the gel had hardened, we started the electrophoresis. W removed the tape from the open 
ends of the gel platform and withdrew the gel comb, taking care not to tear the sample wells. We placed 
the gel-casting platform containing the set gel in the electrophoresis tank. We added sufficient 
electrophoresis buffer to cover the gel to a depth of about 1 mm. We prepared the DNA sample by 
adding the appropriate amount of loading buffer to a volume of 20 µL. We loaded each well with 20 µL 
of sample. We included the appropriate DNA molecular weight markers to label our gel at the DNA sizes 
we were expecting. We then run the gel at 100 V for one hour and photographed it.  
Results 
 
PLD Purification 
The majority of data involves our efforts to optimize the purification process for PLD.  Initially, 
we managed to achieve a concentration of 378.1 and 201.5 µg/mL respectively in our first two 
purifications. Figure 10 shows the SDS-PAGE that we ran using samples from different stages of the 
purification in order to analyze our collection of PLD. For all figures, mM notations refer to imidazole 
concentration of the buffer solution. We can see that during the washing process, we are removing 
impurities along with some PLD seen at 32.1 kDa. This can be seen in lane 8, where a significant band of 
PLD is visible. A similar, but decreasing pattern of band darkness can be seen for lanes 10 and 11 which 
are the subsequent washes. For PLD prep 1 (lane 12) we can see some protein contaminants with 
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heavier molecular weight. For PLD prep 2 (lane 13), we can also see a contaminant, but one with a 
molecular weight only slightly larger than PLD.   
 
 
 
 
 
 
PLD Sample 
Concentration 
(µg/ml) 
Notes 
UPNY 3a 32.7 
Old culture 
wash 1 
UPNY 3b 41.7 
Old culture 
wash 2 
UPNY 4a 680.8 
New culture 
wash 1 
UPNY 4b 381.2 
New culture 
wash 2 
UPNY 5a 
408.6 
Two BCAs  
423.38 
UPNY 5b 
234.4 
Two BCAs 
210.1 
UPNY 5c 329.2 Not dialyzed 
UPNY 5d 531.8 Not dialyzed 
Table 1: Spring 2012 PLD Yields, BCA refers to Bicinchoninic Assay 
use to measure protein concentration. For UPNY 5a and 5b, two 
BCAs were carried out, with slight variation in result.  
Figure 10: SDS-Page Gel A: 1- Marker; 2- Culture supernatant; 3- Flow through with 
binding buffer ; 4- Flow through with BB; 6- 2
nd
 10mM imidazole wash; 7- 3
rd
 10 mM wash; 
8- 1
st
 300 mM wash; Gel B: 9- marker; 10- 2
nd
 300 mM wash;  11- 3
rd
 300 mM wash; 12- 
UPNY PLD 1; 13- UPNY PLD 2 
1     2     3     4      5     6     7     8         9   10   11    12  13  
32.1 kDa 
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Over the course of the spring semester 2012, we conducted several rounds of purification. The 
various sample concentrations can be seen in Table 1. Previously, we had been conducting only one 
elution at 300 mM imidazole for each purification. However, for sample 3 onwards we used a 500 mM 
imidazole elution buffer and 2 rounds of elution. The number following ‘UPNY’ indicates the elution 
prep number and the letter indicates the elution. For each purification, we conducted two elutions per 
sample with a soak time of 15 minutes (compared to the previous 6-8 minutes). For UPNY 3, we had to 
temporarily halt the procedure during the large culture step, before adding IPTG. As a result, we had to 
store the large tissue culture in the cold room and so the cells probably died.  
When we started the next purification we purified the PLD from the bacteria storied in the cold 
room (UPNY 3), in addition to the new PLD culture (UPNY 4). The old culture gave a very low PLD yield as 
expected, but with the new sample, we were quite successful with a concentration of 680.8 μg/mL using 
500 mM imidazole in the first 2 mL elution. We attempted a second elution with the same imidazole 
concentration and got a relatively high value of 381.2 μg/mL for our 2 mL collected. This indicated to us 
the necessity of continuing using two elutions to collect the maximum amount of PLD possible. We 
proceeded to carry out a third purification (UPNY 5). However, mistakenly, 3.5 times the normal elution 
volume was used. For PLD preparation 5, elutions a through d refer to four different fractions that were 
collected. Despite our excessive elution volume, 7 mL, we still collected a concentration over 400 μg/mL. 
Figure 11 shows the SDS-PAGE results from our next purification, UPNY PLD 3. As we had 
learned from the BCA, the PLD content was quite low. In lane 7 and 8, the PLD bands at ~37 kDa (PLD is 
31,500) are very faint. Additionally, in the first elution, there was a second band located lower than the 
PLD band. Lanes 4-6, which were the washes, also contain small traces of PLD, particularly lane 5. 
However, these amounts are low. In Figure 12, one can see the gel run with samples from PLD 4, the 
new culture. The PLD bands are more pronounced in lanes 7 and 8 at the 32.1 kDa mark. However, there 
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Figure 13: SDS-Page (2/23) of PLD Purification 5  
Lane 1- Marker; Lane 2- Flow through wash 1; Lane 3- Flow 
through wash 2; Lane 4- Flow through from wash 2; Lane 5- 
PLD Elution 1 (5a); Lane 6- PLD Elution 2 (5b) ; Lane 7- PLD 
5c; Lane 8- PLD 5c; Lane 9- Autoclaved PLD 1; Lane 10- 
Autoclaved PLD 2 
32.1 kDa 
10 kDa 
  1      2      3     4    5     6    7    8   9   10 
appears to be some impurity or other protein appearing in lane 8 much higher than the PLD band. The 
lanes containing our washes do not have visible PLD bands, indicating that we did not lose a significant 
amount of protein during the isolation process.  
Figure 13 shows the gel used to run samples from UPNY PLD 5 as well as samples of autoclaved 
PLD from last semester. Unlike before, this and succeeding gels were run under reducing conditions 
(loading dye contained β-mercaptoethanol), which may have contributed to the higher resolution. PLD 
Figure 11: SDS-Page (2/23) of PLD Purification 3  
Lane 1- Marker; Lane 2- Cell lysate; Lane 3- Resin S/N; Lane 
4- Flow through imid. wash 1; Lane 5- Flow through wash 2; 
Lane 6- Flow through wash 3; Lane 7- PLD 3a; Lane 8- PLD 3b 
 1       2      3     4       5    6      7      8 
32.1 kDa 
10 kDa 
Figure 12: SDS-Page (2/23) of PLD Purification 4  
Lane 1- Marker; Lane 2- Cell lysate; Lane 3- Resin S/N; Lane 
4- Flow through from wash 1; Lane 5- Flow through wash 2; 
Lane 6- Flow through wash 3; Lane 7- PLD 4a; Lane 8- PLD 4b 
  1      2      3     4    5     6    7    8 
32.1 kDa 
10 kDa 
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5a and b had high concentrations of PLD which can be seen in the very prominent bands in lanes 5 and 6 
at ~32,000 Da. PLD 5b and c had smaller amounts of PLD at expected. However, we noticed a lot of 
unwanted contaminants in the sample both above and below the PLD bands in lanes 5 and 6. Much of 
these were washed out in the three washes on lanes 2-4, however some remains. We could also see 
levels of PLD (higher than the c and d elutions) in wash 1 and 2 especially. Finally, lanes 9 and 10 
contained the autoclaved PLD from samples UPNY PLD 1 and 2. As can be seen, the autoclaving process 
completely degraded the protein, leaving small bands distributed from 31,000 Da and smaller, ruling out 
the possibility that this could serve as an alternative form of inactivation.  
Mutant Transformation 
 
Once we received the plasmid encoding the His-tagged PLD with His20 mutation from Genscript, 
we transformed it into DH5-α cells and selected 10 colonies using ampicillin. To test the transformation, 
we used restriction analysis with EcoRI and PvuI on plasmid DNA obtained from transformed bacteria. 
Figures 14 and 15 show the results of our digests when run on an agarose gel. We used a combination of 
double enzyme digests (DD) in wells 9 and 10 on the first gel and wells 3 through 10 on the second gel, 
and three pUC19 transformation controls. We used single enzyme digests to test just mutant line 1 
(M1). We were expecting that the mutant double digest would show bands at 3531, 950, and 751 bp. 
Figure  14: Agarose gel on 1st 
TransformationLane 1- 1kb ladder; Lane 
2- 100 bp ladder, Lane 3- Control 1 DD; 
Lane 4- C2 DD; Lane 5- C3 DD; Lane 6- 
Mutant 1 uncut;  Lane 7- M1 EcoRI; Lane 
8- M1 PVUI; Lane 9- M1 DD; Lane 10- 
M2 DD  
 
3531 bp 
 
 
 
950 bp 
751 bp 
 1     2     3     4      5      6       7     8     9     10 
Figure 15: Agarose gel on 1st 
Transformation 
Lane 1- 1kb ladder; Lane 2- 100 bp 
ladder, Lane 3- M3 DD; Lane 4- M4 DD; 
Lane 5- M5 DD; Lane 6- M6 DD;  Lane 7- 
M7 DD; Lane 8- M8 DD; Lane 9- M9 DD; 
Lane 10- M10 DD 
1    2      3      4     5       6     7      8      9     10 
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EcoRI did not seem to work, possibly due to age of the enzyme. For the double digests, on the control 
lanes three bands can be seen representing the 3 cuts made by the enzymes which were expected at 
3531, 950, and 751 bp. On the second gel (figure 15), mutants 4, 5, 7, and 8 have very little DNA 
appearing in bands. The only lanes with prominent bands that matched expected sizes were 3 and 6.   
Using the resulting cell colonies from the first transformation we carried out two purifications, 
PLD 6 and 7 with mutant clones 3 and 5 from figure 15 respectively. But, as can be seen in table 2, PLD 
yields were low. Even though the previous transformation appeared to be successful according to 
plasmid DNA digests, we decided to re-do the transformation in the hopes of increasing yields. The 
results on the gel can be seen in figure 16 and 17. The warped nature of the bands is evident. The uncut 
controls in lanes 2 and 3 did not move for the most 
part as can be seen from the DNA that remains in 
the well. However, there are faint bands extending 
across, midway on the gel, till lane 6 at around 751 
bp. Lane 7, 8, and 9 all exhibited 2 consistent bands 
as a result from PVUI’s two cutting sites on the 
plasmid, as we expected. The second gel, figure 17, shows the double digests. Results are mostly 
uniform across the gel. In particular, lanes 3, 5, 7, and 8 had the best results, showing our three 
Sample Conc. (µg/ml) Notes 
UPNY 6a 36.2 Ave. of 2 BCAs 
UPNY 6b 23.9 Ave. of 2 BCAs 
UPNY 7 36.5 
 
UPNY 8a 16.39 
 
UPNY 8b 41.41  
Table 2: First Purification of Mutant PLD 
1  2  3    4    5   6    7    8   9   10     
10 
Figure 16: Gel 1 of digests on 2nd 
transformation attempt 
Lane 1- 1kb ladder; 2- C1 uncut, 
3- M1 uncut; 4- M1 EcoRI; 5- M3 
EcoRI ; 6- M8 EcoRI;  7- M1 PvuI; 
8- M3  PVUI; 9- M8 PvuI; 10- 100 
bp ladder 
1  2    3  4    5    6    7   8   9  10     
10 
Figure 17: Gel 2 of digests on 
2nd transformation; Lane 1- 1kb 
ladder; 2- C1 double digest, 3- 
M1 DD; 4- M2 DD; 5- M3 DD; 6- 
M4 DD;  7- M5 PVUI; 8- M6 DD; 
9- M8 DD; 10- 100 bp ladder 
 
3531 bp 
 
950 bp 
 
751 bp 
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expected bands at 3531, 950, and 751 bp.  
Using these newly transformed bacteria (mutant clone 7), we carried out another PLD 
purification. We hypothesized that a possible reason for the lack of significant PLD yield was changed 
solubility of the PLD due to the site specific mutation. As such, we included an additional solubilization 
step to check if the mutated PLD was insoluble in the cell lysate during our purification procedure. The 
result was UPNY PLD 8a and 8b. In table 2, the PLD concentration is even lower than that of 6 and 7, 
both of which were already negligible.   
Troubleshooting of Mutant and Wildtype Purification 
 
Multiple purifications of both mutant and wild type PLD were done in my efforts to maximize 
the yield. Initially, preps 6a through 14b (figure 18 and 19), as can be seen from the graph below, 
protein concentrations were below 150 µg/mL. However, with changes to purification technique, later 
batches of mutant PLD eventually crossed above 150 µg/mL (prep 14c) and reached almost 200 µg/mL 
Figure 18: Preps of Mutant PLD 
according to elution reagent used 
Legend 
E1- 500 mM imidazole  
E2- 2nd 500 mM imidazole 
EDTA1- 100 mM EDTA 
EDTA2- 200 mM EDTA 
ph 4- pH 4 Binding Buffer 
pH 5- pH 5 Binding Buffer 
 Figure 19: Preps of Wildtype PLD 
according to elution reagent used 
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(prep 15b). However, this was still a ways from our minimum of 500 µg/mL. The two tables, figures 18 
and 19, illustrate the various yields for protein purifications, both mutant and wild type over the course 
of the summer. The tables show the type of elution used to collect the PLD.   
Our primary goal recently has been to purify mutant PLD. As such, we carried out analysis to 
identify which culture condition promotes the most mutant PLD synthesis. One of our first 
troubleshooting tests was based on the fact that our cell pellets seemed somewhat small. We thought 
that perhaps the cells were not growing well. Separate from our purification attempts, we cultured the 
bacteria at different temperatures and induction times with IPTG to compare PLD levels. The results can 
be seen in figure 20 and 21, which were the SDS-PAGE of culture lysates and the Western blot probed 
for PLD using hybridoma supernatant positive for anti-PLD antibodies. Each band contains samples from 
a condition of culture temperature, induction time, and samples using the old and new sonicator. PLD 
appears right near the 32.1 kDa band on the marker. It seems that 37 degrees with 3 hours of induction 
is the faintest. Using the blot, we can compare the darkness of the PLD bands to identify which culture 
condition had the most protein with volume kept constant. The legend shows the contents of each lane, 
applying to both figures. 
Alternatively, we hypothesized that the site specific mutation could have altered the folding of 
the protein and that this might have affected the solubility of the protein in the binding buffer. We 
32.1 kDa 
M  S   L  W  
P
Figure 20: PLD Western blot on cell lysate 
at different culture conditions 
Figure 21: SDS-PAGE on cell lysate at 
different culture conditions 
SDS-PAGE:  
Lane 1- Marker 
Lane 2- PLD positive control.  
Lane 3- 37º with the old sonicator.  
Lane 4- 37º with the new sonicator.  
Lane 5- 36º 3 hours.  
Lane 6- 36º 5 hours.  
Lane 7- 37º 3 hours 
Lane 8- 37º 5 hours 
Lane 9- 38º 3 hours 
Lane 10- 38º 5 hours 
32.1 kDa 
   1    2      3     4    5      6     7     8      9    10     1    2     3     4     5     6    7     8     9    10  
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created a solubility testing assay to check the amount of PLD in various cell culture components. The 
flowchart below exhibits our efforts. Each section was solubilized with a specific technique and then run 
on a gel to compare amounts of PLD. A Western blot allowed us to better visualize the comparative 
amounts of only PLD in figure 23. Lanes are labeled by their corresponding number in the solubilization 
flow chart.  
 Following the solubilization tests, we hypothesized that another explanation for low yield could 
be if the His-tag of the mutated PLD bound in a different way to the Co2+ of the TALON resin. We usually 
eluted with 500 mM imidazole solution, which we considered to be very strong. However, if the 
mutated PLD’s affinity was higher than we might have needed stronger elution regents. In conversation 
with the company, we decided to try a pH 4 and 5 elution in addition to 100 mM and 200 mM EDTA to 
strip the resin. Figure 25 shows the comparative effects when we use different elution reagents. PLD 14 
Figure 23: Western Blot on 
solubillization protocol. Lane 
labels correspond to fractions 
labeled in figure 22. Lane 9 is the 
PLD prep from fractions 4 and 6. 
Figure 24: Solubilization Gel on 
solubillization protocol. Lane 
labels correspond to fractions 
labeled in figure 22. 9 is the 
PLD prep from fractions 4 and 6 
   M     2     3    4     5    6   7    8      9 10 M  2    3   4   5  6     7     8    9   10 
PLD 
Figure 22: Solubilization Protocol. Numbers refer to lanes in figures 23/24  
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    M    S   L   B   B W  W  14a b  c                 M  15c d e  
32.1 
kDa 
 M   S    L   B   B   W W W 15a b   
32.1  
17.4 kDa 
38.2 
kDa 
Figure 25: Elution Variation. M: Marker; S: Cell culture supernatant; L: Cell lysate; B: Binding 
buffer rinse; W: Imidazole wash, Numbered PLD preps correspond to those listed in figure 18 
involved pH 5 elution, but the absence of proteins in the band proves that it was unsuccessful. On the 
other hand, 15 c and d contained an imidazole wash and had more PLD visible in the Western blot. 
The next method of testing to ensure that there were no obvious errors with our protocol: were 
we losing PLD when we were washing? Did the PLD inadequately bind to the resin in the beginning? 
While this step was included in the protocol for each purification round, in prep 15 we carefully 
observed the results. By running various samples on a gel (Figure 26), we were able to compare the 
approximate protein concentration. The washes show that only small amounts of PLD were present 
(lanes 9d and 12b). Comparing the cell lysate (B) lane in both the first and second gel to the clarified 
supernatant (S), we can see how much PLD was transferred into the column with the resin. 15d and e 
also show the importance using EDTA as an alternative (figure 25). It was highly effective at 100 mM and 
produced larger yields of PLD. Figure 27 shows the progression of purification over the course of the 
summer on mutant PLD purification.  
           M  S   L  B  W  W   12a 12b M   S    L   W  9a  9b W  9c  9d   + 
Figure 26: PLD testing the importance of EDTA as a powerful 
eluting agent 
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The final change was reducing the intensity and duration of sonication to lyse the cells. 
Furthermore, through research done by Dr. Karen Molinder, the concentration of imidazole used to 
elute PLD from the column was changed to better reflect protocols suggested by the manufacturer. The 
results were very high yields of 546.7 µg/mL and 1516.3 µg/mL for the 150 mM imidazole and 100 mM 
EDTA respectively (carried out by Dr. Molinder). The SDS-PAGE in figure 28 shows the relative protein 
Figure 28: SDS-PAGE on mutant PLD sample with  new 
protocol including changed sonication intensity and 
duration. M: Marker; L: Cell lysate; B: Rinse with 
equilibrium buffer; W: wash with imidazole; 7: 1.5 µg 
PLD imidazole-eluted; 8: 3 µg PLD EDTA-eluted; 9: 1.5 
µg PLD imidazole-eluted; 10: 3 µg PLD EDTA-eluted 
M    L      B     B      W    W      7     8      9     10 
Figure 27: Graph showing mutant PLD purification between January 
2012 and August 2012 as the protocol was changed 
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presence indicative of the high concentration. Each sample (the imidazole and EDTA elution) was run at 
1.5 µg and 3 µg quantities respectively in lanes 7/8 and 9/10.  
 We continued to use the new protocol for wild type PLD purification to see how high the yields 
could be made. Figure 29 shows the results of purification for PLD 19. Yields were very high. PLD sample 
19a (eluted in 150 mM imidazole) was 233.93 µg/mL and PLD 19b (eluted in 150 mM EDTA) was 925.13 
µg/mL, a record high. As can be seen in figure 29, the concentrated PLD samples in lanes 8 and 9 are 
significantly darker than the others. However, we can see a significant amount of protein contaminants 
present in all the lanes, darkest in the concentrated PLD rather than being successively fainter. The 
difference in darkness of the PLD bands between the cell lysate (L) before incubation with resin and the 
first equilibrium buffer rinse lane (B) shows that the majority of PLD did bind to the TALON resin. 
Furthermore, all of the rinses (B) seem to have washed away unwanted contaminants but not excessive 
amounts of PLD. However, it is important to note that PLD samples were loaded at a standard volume 
without calculating and ensuring that a uniform amount of PLD was loaded; as a result, direct 
comparison of band darkness is misleading.  
Figure 29: SDS-PAGE of Mutant PLD with new protocol and 
sonication conditions. M: Marker; L: Cell lysate; B: Rinse 
with equilibrium buffer; W: wash with 10mM imidazole in 
equilibrium buffer, 19a: PLD eluted in 150 mM imidazole, 
19b: PLD eluted in 150mM EDTA, +: positive PLD control  
 M      L       B     B       B      B    W   19a  19b    + 
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Another round of purification was attempted, this time with the addition of an additional wash 
step with 10 mM imidazole equilibrium buffer to determine if contaminants could be better removed. 
The concentration for PLD 20a (eluted in 150 mM imidazole) and 20b (EDTA) were 396.22 µg/mL and 
841.38 µg/mL respectively. This was interesting considering that the imidazole-eluted elution rose by 
100 µg/mL from purification 19. However, the EDTA-elution decreased by about 100 µg/mL. SDS-PAGE 
was not done for this prep.  
Discussion   
 
The results of the protein purifications have helped us determine whether our protocol changes 
have been effective.  From our analysis of SDS-PAGE gels in the summer of 2011, we made changes to 
the protocol. Earlier purifications had been done with 50 mM imidazole washes and we found that those 
removed some of the PLD. As a result, we decreased the imidazole wash concentration to 10 mM to 
prevent loss of PLD. In comparing techniques, we noticed a difference in the SDS-PAGE of the flow 
through for both washes shown in figure 10. The SDS Page from our second purification attempt is also 
shown in figure 10. As expected, in lanes 2 and 3 we can see significant impurity in the sample that is 
then removed during the initial wash steps. In the lanes 8-10, with the 300 mM elution, we can see the 
presence of a band indicating PLD, showing that our purification was successful.  
When we purified that sample UPNY 2 (lane 13 of figure 10), we could see a much stronger band 
of pure PLD compared to PLD 1. However, there is also a larger protein that wasn’t present in earlier 
stages of the purification. We are unsure what that could be because it did not appear earlier in the 
washes. It might be some protein that bound strongly to the resin due to presence of histidine and was 
eluted off the column under these conditions. Compared to our first sample of PLD (lane 12, figure 10), 
UPNY 2 seems to be purer than UPNY 1. There are multiple bands of contaminants in our first sample 
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that were not completely removed by the purification process. While we were able to collect fairly pure 
PLD in these first two preps, our concentration was low. We hypothesized that these early low yields 
could be due to a malfunctioning sonicator. If it was not working correctly, the E. coli would not have 
been completely lysed, therefore when we discarded the pellet, much of the PLD would have been 
trapped in the unlysed cells and debris. As such, we decided to dedicate the next steps of the project to 
optimizing the yield.  
During the spring of 2012, we spent time altering purification techniques. With our efforts to 
purify wild type PLD, we received greater concentrations due to changes in our elution strength. We 
increased the concentration of our imidazole elution buffer to 500 mM from the previous 300 mM. 
Figure 11 shows the SDS-PAGE purification 3. Comparing the difference in PLD band intensity in lane 2, 
the cell lysate, with lane 3, the discarded supernatant after binding between PLD and the resin, it is clear 
that the resin bound most of the PLD in the sample, indicated by the faint band at 31.5 kDa in lane 3. We 
also increased the soaking time for the elution to 15-30 minutes, allowing us to maximize the collection 
of PLD 4 (figure 12) and 5 (figure 13) which can be seen in table 1. It was hypothesized that some PLD 
may be left bound to the resin after we finish elution. We realized that when we eluted PLD off the resin 
twice, we could collect more PLD. Lane 6 of figure 13 shows the results of the second elution, still a 
significantly high concentration (234.4 µg/mL). We realized that we should continue using two elutions 
to collect all the PLD possible. With PLD 5, 3.5 times the elution volume was accidentally added. Despite 
more dilution, the relatively high concentration of PLD, 423 (UPNY 5a) and 234 μg/mL (UPNY 5b) 
respectively, suggests a high protein concentration had we eluted in only 2 mL of imidazole solution.  
As mentioned earlier, figures 11-13 show the results of our SDS-PAGE on our wild type PLD 
samples. In Figure 11, it is clear that there is a significant presence of PLD in both our ‘a’ and ‘b’ samples, 
indicated by a prominent band at ~31.5 kDa. A second band appears in lane 7; however we are unsure 
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what it represents. Since that gel contains PLD 3, the old culture, it is possible that the band is made of 
some proteins secreted by the older or dying cells. Lanes 4, 5, and 6, our washes, all contain slight traces 
of PLD, indicating that we lost small amounts of PLD with our wash. 
Figure 12 shows the samples from PLD 4. Unlike figure 11, we did not lose any PLD with our 
washes. There is a very prominent PLD band in lane 7, indicative of a higher concentration. The second 
elution, 4b, also shows PLD, however it has a large amounts of proteins. We are unsure what the 
additional bands are. We also cannot explain why they were unseen on the gel throughout the washes 
and the first elution, only to appear at the end possibly because they bound tightly to the column. The 
final gel, figure 13, shows the results of wild type PLD 5. Intense PLD bands in wash lanes 2-4 show that 
we were losing a large amount of PLD earlier along with many other impurities. In lanes 5 and 6, there 
are very intense PLD bands, reflective of the measured high concentration. However, there are other 
protein bands as well, representing unknown contaminants. The final lanes, 9 and 10, were our 
autoclaved PLD samples from a previous prep. The autoclave inactivation was clearly effective as the 
proteins were virtually destroyed, degraded to into a vast collection of protein fragments. The complete 
breakdown suggests that it would be unsuitable as a vaccination since the protein was degraded.  
To use the mutated plasmid to express PLD, we carried out a transformation and restriction 
digest. The results in figures 14 and 15 show our double digest controls (gel 1, lanes 3 and 4), confirming 
that our transformation worked, with three clear bands indicated the total three cuts by PvuI and EcoRI. 
However, lane 5 seems to have faint bands perhaps a result of a loading error. On gel 2, lanes 3 and 6 
show the best digests with three clear bands. As a result, we used mutant clone 3 (lane 3) for our 
purification. Our concentration for mutant PLD 6 was incredibly low; despite following the full protocol, 
we achieved a low yield of 36.2 μg/mL on the first elution. We re-purified with the same mutant line to 
ensure that we had not made errors the first time. Mutant UPNY 7 was 36.5 μg/mL, still very low. Our 
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restriction digest confirmed that the transformation had successfully taken place. However, to ensure 
that we had not made a mistake, we repeated the transformation with the mutant PLD expression 
plasmid.  
The results can be seen in figures 16 and 17. We were unsure why the gels were so warped. One 
explanation was that the TAE buffer we used to run the gel was quite old. This might have caused solute 
precipitation within the buffer and obstructed even flow of the current. Fortunately the gel was 
readable. Compared to the first digest, the bands were more consistent; perhaps a result of newer 
enzymes. Our uncut DNA in lanes 4, 5, and 6 of gel 1 were as expected. In lanes 7, 8, and 9 there are only 
two bands, indicative of the two cuts made by PVUI. Gel 2 had all of our mutant double digests. We 
found that all of the cultures contained our plasmid. This was not surprising since theoretically the cells 
shouldn’t have survived in ampicillin culture without the plasmid inserted correctly; the construct 
contained the ampicillin resistant gene. We found that mutant clones 1, 3, 5, and 8 had the strongest 
bands in the double digests, as we expected at 3531, 950, and 751 bp respectively. As a result we chose 
mutants clones 1 and 3 respectively, for our next two purifications.  
After consultation with the company that manufacturers the TALON resin, Clontech (Mountain 
View, CA), we concluded that the low yields might be due to a solubility problem of the mutated 
protein. As a result, we added an additional component to the purification protocol. Rather than throw 
away the pellet after sonication and centrifugation, we solubilized proteins from the insoluble pellet 
component, hoping to find some PLD in this layer. We then purified the various components using the 
TALON column. UPNY 8 a, b, c, and d were the results of these efforts. There were some mistakes when 
carrying out the new protocol. A centrifugation was missed midway and, in spite of our efforts to correct 
it, our yield was very low: 16.39 μg/mL and 41.41 μg/mL for our first and second elutions respectively. 
We hypothesized that the inclusion of cell debris had lowered the TALON resin’s affinity for PLD through 
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non-specific binding. As a result, we attempted a ninth purification on the same protocol as well, this 
time ensuring that all centrifugation steps were done correctly, so that cell debris was removed before 
addition of the beads. However, this once again little to no PLD was obtained. 
The next testing assay we carried out was to identify the optimum culture conditions for the E. 
coli to express the mutant PLD. Figures 20 and 21 show the gel and Western blot from the experiment. 
First of all, it becomes apparent that at each discrete temperature condition, the 5 hour induction allows 
for maximal PLD expression (by comparing the darkness and size of the band in the blot). We also used 
the assay to test the efficiency of our new sonicator. Viewing lanes 2 and 3 on the gel, one can see that 
the new sonicator released more proteins, as can be seen from the darker collection of bands. Usually, 
our E. coli is cultured in the 37 degree warm room. However, we noticed that the 38 degree conditions 
seemed to provide maximum protein expression. This is something that would need to be explored 
further to identify if a higher temperature would be optimal for growth. For the purposes of 
experimentation, we decided that the 37 degree culture times were sufficient for our purification.  
 Since preps 8 and 9 did not work, we conducted a complete solubility assay to identify which cell 
fraction the PLD was in, as can be seen in figures 23 and 24. The flow-chart for the various components 
is in figure 22. We were surprised to see that PLD remained in every sample, indicating that PLD gets 
trapped in the cell pellet as well. We found that when we used urea to solubilize the pellet (lane 7), we 
were able to isolate PLD. Using SDS, a denaturing agent, was not necessary since it did not produce that 
much more PLD (lane 8) than urea (lane 7). We noticed that the lane containing a sample grown at 37 
degrees with 3 hours of induction was faint, but we suspect that that could have been caused by 
experimental error during loading of the sample. From examining the Western blot and comparing the 
relative quantities of PLD in each component, we concluded that there was enough PLD in the clarified 
cell lysate (lanes 4 and 6) for us to use our regular purification protocol  
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 The biggest changes made were to our elution process. Previously we had used 500 mM 
imidazole solution to displace the PLD from the Co2+ ions in the TALON resin. We suspected that due to 
the mutation perhaps the conformation had changed and the PLD bound very strongly to the resin, so 
only smaller amounts were eluting off. In conversation with Clontech, we were advised to try acidic 
binding buffer to elute. Figure 25 shows the alternate elution reagents that we used. 15a, 14a, and 14b 
were the acidic elutions of pH 4 and pH 5. However, as can be seen in the lanes, there is no significant 
protein content, let alone PLD. Hence we concluded that the acidic elution buffer was ineffective.  
Next we tried 100 mM EDTA, as can be seen in 15 d and e. Both contained detectable protein in 
the 32.1 kDa region, where we expected PLD. This was an amount that was significantly high, especially 
considering that two elutions with imidazole had already taken place meaning that all the PLD had not 
been eluted from the column. We concluded therefore that EDTA seems to be the best eluting agent 
that we tried. By using EDTA earlier in the process, before the use of an imidazole elution, we can 
maximize the concentration. As a chelating agent, EDTA irreversibly strips the cobalt off the sepharose 
backbone of the TALON beads. Like imidazole, EDTA can be removed from the PLD using dialysis in PBS. 
However, since the Co2+ was removed from the resin, the TALON resin is no longer usable and must be 
replaced. Once we started using EDTA, our yield increased tremendously.   
 Our final troubleshooting step involved basic action to ensure that we were not losing PLD due 
to lack of binding to resin or during washing with low-concentration imidazole. Figure 26 shows our 
routine gels to test the flow through that we collected during the purification process. As can be seen 
from the wash (W) lanes, numerous impurities are being washed off from the column. However, 
compared to the amount of PLD in the final eluted sample, only small amounts of PLD are being washed 
away. Therefore, we were able to conclude that we were not losing PLD during the wash process. 
Patwardhan Honors Thesis 38 
 
To determine whether or not our PLD was binding to the resin, in the second gel of figure 26, we 
can compare the protein content of the lysate (L) band before incubation with the resin to the binding 
buffer (B) band, representing the supernatant after incubation. The band in the buffer (B) lane shows 
the amount of protein that was retained in the resin. As can be seen, the difference is noticeable, 
particularly in the 32.1 kDa region of the gel, where the PLD is located. We were able to conclude that 
the PLD was indeed binding to the resin. This ruled out the possibility that protein losses were occurring 
even before the column purification started. As a result, we have concluded that our main problem with 
expressing and purifying mutant PLD was with our elution methods. Our yields increased dramatically 
between spring 2012 and the end of summer, as can be seen in figure 27.  
During the fall of 2012, research was done by Dr. Karen Molinder to determine how our protocol 
differed from that of the various manufacturers’ instructions and that of other labs. Dr. Molinder 
determined that many research groups and manufacturers had used alternate reagents and sonication 
times in order to purify. The protocol was changed, cutting sonication time drastically. Rather than using 
500 mM imidazole to elute, we started using a first elution of 150 mM imidazole, followed by 100 mM 
EDTA. In the first prep with the new protocol, there was a significant rise in yield of mutant PLD: 546.7 
µg/mL for the imidazole elution (KM 1a) and 1516.3 µg/mL for the EDTA elution (KM 1b) compared to 
previous preps. We hypothesize that the excessive sonication of the previous protocol was having a 
deleterious effect on the PLD. Despite the fact that the process was done on ice, the PLD solution would 
rise significantly in temperature. It is highly likely that some of the protein was being denatured or 
altered in a way so that it would not bind to the Co2+ in the resin.  
Figure 28 shows an SDS-PAGE comparing different components, with the PLD samples equalized 
by amount loaded. Leading up to lane 6, we can observe how a series of washes progressively removed 
impurities. The washes with imidazole (W) removed protein from the column that had not been washed 
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off in the previous samples. We further observed that the use of a preliminary imidazole elution can 
help to remove many of the impurities that remain in the sample even after multiple 10mM imidazole 
washes. Comparing lanes 8 and 10, we can see that the EDTA-eluted PLD is far more pure than the 
imidazole-eluted PLD. These results were a break through and allowed us to continue an effective 
protocol.  
Figure 29 was our next attempt at purification for wild type PLD. We were similarly successful in 
this attempt, with a yield of 233.93 µg/mL for imidazole-eluted and 925.13 µg/mL for EDTA-eltued PLD. 
As can be seen, there are significant contaminant bands in many of the lanes. We can confirm that most 
of the PLD was indeed bound to the resin when we compare the lysate prior to resin incubation (L) with 
the discarded buffer supernatant post incubation (B). There were also many impurities that were 
removed during our buffer washes and during our low-concentration imidazole wash. However, in our 
samples 19a and 19b there is still a high amount of contaminants. In this gel, volumes of loaded samples 
were not selected to ensure an equal amount of protein, so the relative bands cannot be compared to 
ascertain relative sample concentration. Regardless, we can objectively see the high amount of PLD as 
well as contaminant proteins.  
To address this problem, we decided to add an additional 10 mM imidazole wash to the protocol 
to reduce the presence of extraneous protein matter. The result, wild type PLD 20, had similarly high 
yields, with a 396.2 µg/mL for imidazole-eluted and 841.4 for EDTA-eluted. Interestingly, the yield for 
our EDTA-elution dropped by 100 µg/mL while the yield for imidazole rose. We were expecting yields to 
drop slightly as a result of the PLD lost during the additional wash, however that wasn’t the case. Due to 
our improvement in purification technique, we were able to collect significant amount of both wild type 
and mutant PLD.  
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To apply our results on PLD purification and inactivation, the lab has expanded vaccine 
development. Using the help of the Biology 330: Immunology class, the laboratory initiated a mouse 
model for the different PLD vaccines. The first vaccine component tested was formalin-inactivated PLD, 
the most common component of the commercial sheep vaccine. Since the formalin crosslinked the PLD, 
the protein was inactive and could be injected into the mice without being toxic. However, the formalin 
itself is highly toxic and, if inadequately dialyzed out, could have deleterious effects on the mice. Large 
amounts of PLD are lost during the formalin-inactivation process due to precipitation and “clumping”. As 
such, we hoped to test alternate forms of inactivated PLD. 
 The mutant variety of PLD protein was the second vaccine component to be tested. The 
genetically inactivated recombinant protein was purified and used to vaccinate the mice. Since the 
protein is almost identical to the wild type variety except for the active site (residue 20), we expected 
that it would have similar antigenic properties to regular PLD. The purification of mutant PLD is far easier 
and more efficient than the formalin-inactivation of wild type PLD. Furthermore, there is no worry of 
formalin-toxicity to the mice.  
 The lab’s final mouse model vaccine component was a DNA vaccine designed for expression in 
mammalian cells. Using services provided by Nature Technology (Lincoln, NE), Dr. Molinder selected the 
NTC8682 vector that allows for expression of secreted protein in mammalian cells. The proteins are 
targeted for secretion by the cell through use of TPA (tissue plasminogen activator) signal peptide. The 
proprietary selection system by Nature Technology does not need antibiotics but, rather, sucrose in the 
growth medium.  The vectors express an RNA anti-sense strand called RNA-OUT that represses 
expression of counter-selectable marker SacB. SacB encodes for the production of levansucrase. This is 
toxic when combined with sucrose, so plasmid selection is carried out with the addition of the sugar to 
the growth medium (Nature Technology 2011).  
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The Immunology class immunized four groups of mice (A through D), each consisting of four 
mice that were immunized with one of the three different vaccine components tested. Group A was 
immunized with formalin-inactivated PLD. Mice in group B as well as C1 and C2 were immunized with 
mutant PLD. Finally, C3, C4, and D-group mice were immunized with the DNA vaccine. Mice were bled 
regularly and sera were collected for testing by ELISA. Samples were then tested for IgG antibody 
response to both wild type and mutant PLD using an ELISA. Figures 30 and 31 show the initial results 
from this trial, one graph showing the mouse anti-wild type PLD antibody response and the other 
showing the mouse anti-mutant PLD antibody response. ELISAs were carried out by Margaret 
Winterkorn and I analyzed the data. The displayed values are a ratio of the measured optical density to 
the positive and negative controls used on the plate.  
Unfortunately, the sera for bleed dates after 22 days from formalin-inactivated PLD immunized 
mice were finished and serum from two out of the four mice was unaccounted for. For this group, 
averages were calculated from the two available samples. Figures 30 and 31 show the averaged murine 
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Figure 30: Mouse IgG response to wild-type PLD divided by immunization group and 
graphed according to the number of days from immunization that sample was drawn. 
Group averages displayed along with standard deviation bars. 
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antibody response to both wild type and mutant PLD based on immunization administered. As can be 
seen in figure 30, formalin-inactivated PLD and DNA vaccine mice did not exhibit strong immune 
responses to wild type PLD. However, the mice immunized with the mutant PLD reacted very strongly to 
wild type PLD. In figure 31, we can see that the mutant PLD mice exhibit a similar robust antibody 
response to mutant PLD, as we would expect. The formalin-inactivated response has quite a sharp rise 
at day 22. Finally, the DNA vaccine-immunized mice start to show a rising response following 41 days 
from immunization. Large standard deviations for the mutant PLD mice’s response to both wild type and 
mutant PLD indicate inconsistency between the reactions of the six mice. In particular for the last bleed 
dates, three mice had very strong responses while three had very weak responses. This accounts for the 
larger standard deviation bars.  
The data collected from this mouse trial showed a lot of variation in response. However, when 
averaged and displayed along with standard deviation bars, we can follow the primary response to the 
vaccinations. For the response to wild type PLD, the mutant seemed to react the strongest. This was 
-0.20
0.00
0.20
0.40
0.60
0.80
1.00
1.20
0 22 34 41 54 61
R
at
io
 
Days from Immunization 
Anti-Mutant PLD Response 
Formalin-
inactivated PLD
Mutant PLD
DNA Vaccine
Positive Control
Negative Control
Figure 31: Mouse IgG response to mutant PLD divided by immunization group and 
graphed according to the number of days from immunization that sample was drawn. 
Group averages displayed along with standard deviation bars. 
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very heartening, indicating that the site-specific mutation pf the PLD in the vaccine still resulted in the 
production of antibodies that recognize wild type PLD. This presents a large amount of potential for 
vaccine development. The mutant PLD vaccine could be recognized by the immune system the same 
way as wild type PLD, without the toxicity associated with active PLD or formalin-inactivation. 
Unfortunately, there were few sera samples available to study the formalin-inactivated vaccine group. 
However, that response has already been well-documented in mice and has been studied widely due to 
its role in the sheep vaccine. We do not see a significant DNA vaccine response, as we had expected this. 
However, the manufacturers suggest 3-5 boosts for maximum effectiveness. Since we had not boosted 
to that extent, it is possible that, with further boosts, a response can be detected.  
Work with the mouse model will be continued once we have set up our Bio Safety Level-2 
facilities. Along with boosts with all the various vaccine components, the next step will be to challenge 
the mice with live bacteria. We will be able to measure the murine immune response and identify if any 
of the vaccines confer a protective effect against the bacteria. Of particular interest is the mutant PLD 
protein due to its antigenic recognition as both wild-type and mutant PLD. It has a lot of potential as an 
alternative to formalin-inactivated PLD due to its inactivity and non-toxicity. Similarly, the DNA vaccine 
has potential as a “Trojan-horse” of sorts. The host cells will produce mutant PLD within the body itself, 
serving as a sustained source of antigen, to elicit a response and, hopefully, provide protection against 
Corynebacterium pseudotuberculosis.  
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Appendix 
 
Basic Reagents 
 
Tryptic Soy Broth 
30g Tryptic Soy Broth powder (Sigma Aldrich, St. Louis, MO) 
1L ddH20 
Autoclaved 
10x Running Buffer 
30g Tris-Base 
144g of glycine 
10g SDS 
1L ddH20 
pH 8.3 
Store @ room temperature 
Dilute to 1x before using 
 
10x Transfer Buffer 
288.4 g glycine 
60.5 g Tris-Base 
2L ddH20 
1x Transfer Buffer 
100mL 10x Transfer Buffer 
200mL Methanol 
700mL H20 
pH 8.0-8.5 
 
PBS-Tween 20 
1ml Tween 20 
Combine with 2mL PBS 
LB Medium 
10g Tryptone 
5g Yeast Extract 
10g NaCl 
Dissolve above contents in 1L ddH20 
Adjust pH to 7.0 and autoclave to sterilize 
 
IPTG (500mM stock) 
0.357g IPTG 
Dissolve in 3mL water 
 
1M Tris stock 
60.5 grams Tris base in 400 mL ddH20 
pH 8.0 w/ concentrated HCl 
Bring to 500 mL with ddH20 
 
Binding Buffer: 20 mM Tris HCl, 100 mM NaCl 
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5.84g NaCl 
20mL 1M Tris stock 
900mL ddH20 
pH 8.0 (adjust) 
Add ddH20 for a final volume of 1L 
 
MES Buffer 
(formula weight is 195.24) 
3.9 grams MES 
5.84g NaCl 
Dissolve in 800mL ddH20 
pH 5.0 (HCl or NaOH) 
Adjust to 1L with ddH20 
 
Imidazole 
1) 8mL binding buffer + 10mM imidazole 
2) 10mL binding buffer + 150 mM imidazole 
10% Buffered Formalin 
100ml 37% formaldehyde 
900ml ddH2O 
12.0g Na2HPO4 (anhydrous) 
3.0g KH2PO4 (anhydrous) 
Nonbuffered ethanol w/ 0.1% sodium azide (NaN3) 
Previously made by Hector 
 
New Recombinant PLD Purification Protocol: Non-denaturing Conditions 
 
1M NaH2PO4 (200 ml): MW = 120 g/mol 
24 g in total volume of 200 ml  
Note: Will precipitate at room temp.  Warm until dissolved.   
 
1M Na2HPO4 (200 ml): MW = 142 g/mol 
28.4 g in total volume of 200 ml  
 
100 mM sodium phosphate buffer pH 7.0 (1 L) -see Maniatis Vol. 3; Appendix B.21 
42.3 ml of 1M NaH2PO4 
57.7 ml of 1M Na2HPO4 
bring total volume to 1L.  pH to 7.0 
 
1X Equilibrium Buffer    for 500 ml: 
50 mM sodium phosphate buffer  250 ml 100 mM sodium phosphate buffer 
300 mM NaCl     8.77 g NaCl 
pH to 7.0 
 
Imidazole elution buffer (150 mM imidazole) for 100 ml: 
150 mM imidazole in 1x elution buffer    1.02 g imidazole 
pH to 7.0 
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100 mM EDTA elution buffer pH 8.0: 
for 100 ml: use 3.72 g EDTA (MW = 372.2 g/mol) 
 
Start pHing toward 8.0: EDTA will not fully go into solution until nearing this range.   
 
II. Sample Preparation 
(1) Harvest cell culture by centrifugation at 1000 – 3000 g (3500 – 5500 RPM for Beckman JA-10 
rotor) for 15 min at 4C.  Remove supernatant. 
(2) Resuspend the cell pellet by vortexing in chilled 1X Equilibration/Wash buffer.  For cultures < 
100 ml, use 2 ml buffer for every 25 ml of original culture; for cultures > 1L, resuspend the pellet 
in 2% of the original culture volume; for 900-1000 ml culture, use 35 ml buffer.   
(3) Sonicate on ice.  Run three cycles of program 4 (10 sec at 50%: 0.5 sec on; 0.5 sec off.  Keep for 
30 sec on ice in between cycles). 
(4) Transfer lysate to two 50 ml Nalgene specialty centrifuge tubes: Make sure tube masses are 
within 0.2 g. Centrifuge at 10,000 – 12,000 g (~ 10,500 RPM for Beckman JA-17 rotor) for 20 min 
at 4C.   
(5) Carefully transfer supernatant to clean tube without disturbing pellet.  Save small sample for 
later SDS-PAGE.   
 
III. Column Purification 
(1) Thoroughly resuspend the BD Talon resin, then transfer 4 ml slurry to a sterile 50 ml conical.  4 
ml slurry will = 2 ml bed volume of packed resin 
(2) Centrifuge at 700 g for 2 min at 4C to pellet resin.  Discard supernatant. 
(3) Wash resin twice with 10x bed volume of equilibration/wash buffer 
a. Add 10 bed volumes of 1X equilibration/wash buffer and mix briefly 
b. Centrifuge at 700 g for 2 min at 4C to pellet resin.  Discard supernatant. 
c. Repeat steps a. and b. 
(4) Add the clarified lysate from section II to the resin in the conical.  Rotate conical in the cold 
room on a vertical tube rotator for 20 min.   
(5) Centrifuge at 700 g for 5 min at 4C to pellet resin.  Remove as much supernatant as possible 
without disturbing the resin pellet. 
(6) Wash resin twice with 10x bed volume of equilibration/wash buffer 
a. Add 10 – 20 bed volumes of 1X equilibration/wash buffer.  Agitate the suspension 
gently.  Rotate conical on a vertical tube rotator for 10 min.  
b. Centrifuge at 700 g for 5 min at 4C to pellet resin.  Discard supernatant. 
c. Repeat steps a. and b. 
(7) Add 1 bed volume of 1X equilibration/wash buffer to the resin and resuspend by vortexing 
(8) Transfer the resin to a 2 ml gravity flow column with end cap in place.  Allow the resin to settle 
out of suspension at 4C 
(9) Remove end cap and (at 4C) allow buffer to drain into waste container below until it reaches the 
top of the resin bed, making sure no air bubbles are trapped in the resin bed. 
(10) Add 5x bed volumes of 1X equilibration/wash buffer to the column to wash. drain at 4C.   
(11) Optional: If necessary, wash column with 1X equilibration/wash buffer including 5 -10 mM 
imidazole. 
(12) Elutions: Prepare tube for collection. Perform at 4C 
a. Optional imidazole elution: Add 1 bed volume of 150 mM imidazole elution buffer. 
Collect.   
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b. EDTA elution: Make sure column end cap is in place.  Add 1 bed volume of 100 mM 
EDTA elution buffer.  Let resin soak for 30 min at 4C.  Position collection tube, uncap, 
and collect.   
 
 
 
IV. Dialysis: Load G2 Dialysis cassette with needle and syringe 
 
(1) Hydrate membrane 
a. Remove cassette from packaging. Handle cassette by its frame only!! Do not touch the 
membrane with ungloved hands! 
b. Immerse cassette in dialysis buffer (1X PBS) for 2 min to hydrate.  It may be necessary to 
hold the cassette under the surface for the hydration step as the air inside the cassette 
may cause it to float sideways  
c. Remove cassette from buffer.  Gently tap on a paper towel to remove excess.  Turn 
cassette upside down and tap again.  Do not blot membrane!  
 
(2) Add sample: Maximum volume for 3 ml cassettes is 1 ml. 
a. Use 18 or 21 gauge 1 – 1 ½” needle.  Fill the syringe with sample, leaving a small amount 
of air in the syringe 
b. With base of cassette on benchtop, SLOWLY penetrate the gasket through one of the 
syringe ports.  Push needle in just enough to see the open end is in the cavity. 
c. Slowly inject about half the quantity of sample in the syringe. Then withdraw some air 
from the cassette by gently pulling back on the syringe plunger.  Then inject remaining 
sample.   
d. Withdraw some air from the cassette by pulling back on the syringe plunger, to 
compress the membrane windows around the sample.  Stop before windows touch 
needle. 
e. Remove needle from cassette while reatining air in the syringe.  Mark which port you 
used on the cassette.   
 
(3) Dialyze 
a. For the volume of dialysis buffer, use at least 300 times the sample volume.  Float 
cassette vertically in the dialysis buffer.   
b. Stir gently with stir bar – make sure you do not create a vortex that pulls the cassette 
down in contact with the stir bar.   
c. Dialyze 2 hr; change buffer. Dialyze 2 hr; change buffer.  Dialyze overnight 
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(4) Recover sample: use the unused syringe port 
a. Suck some air into the syringe.  Penetrate gasket and push needle in until you can just 
see open end.  Inject air into cassette to inflate and separate the membrane windows 
With needle in place, turn cassette so needle is on the bottom.  Allow sample to collect near port and 
withdraw the sample with syringe.   
 
His-PLD Purification (Old protocol) 
Grow and Sonicate E. coli Bacteria 
1. Streak E. coli bacteria (strand JG52274) containing the 6xHis tag on an LB+AMP plate. The 
bacteria is in the -80°C freezer in the box labeled “Immunology.” 
2. Put the plate upside down in the 37°C warm room overnight, or until ready to pick. 
3. Before picking, make sure you have 500 ml of LB. Right before picking, add 1 ml of 50 mg/ml of 
AMP to 500 ml of LB and swirl. The AMP is currently in the freezer in a 15 ml conical tube at a 
concentration of 50 mg/ml. The final concentration of the LB will be 100 μg/ml. 
4. When ready to use the E. coli, pick an isolated colony and transfer gently into a bacteria culture 
tube filled with 3 ml of LB+AMP. Make sure to sterilize the loop before each use by dipping in 
ethanol and then flaming. 
5. Wrap the plate with Parafilm and store in the cold room. 
6. Incubate the small culture in the 37°C warm room with shaking for 12 hours, or until cloudy. 
7. Pour the small culture into ~500 ml of LB+AMP (100 μg/mL) in a 2 L flask. Put the large culture in 
the 37°C warm room with shaking for 24 hours. 
8. Add 3 ml of 500 mM IPTG (0.357 g of the IPTG into 3 ml of ddH2O). Put the large culture back in 
the 37°C warm room with shaking for 5 hours. 
9. Remove the large culture from the warm room. Pour the culture from the 2 L flask into two 
plastic centrifuge bottles. Try to get each bottle to have the same volume (~250 ml). 
10. Harvest the cells by centrifuging at 7000 rpm for 15 minutes. Use the centrifuge located in the 
room with the -80°C freezer. 
11. Discard the supernatant. Resuspend one of the pellets with 10 ml of binding buffer. 
12. Once the pellet has been resuspended, transfer the cell solution to the other centrifuge bottle. 
Resuspend until the second pellet dissolves. 
13. Transfer the cell solution to a 50 ml conical tube. Fill  up to 35 ml with binding buffer. 
14. Sonication should be done with 1:1 ratio of pulse time and an output amplitude of 80-100%. To 
clean the sonicator, sonicate ~40 ml of ddH2O for two minutes. Gently dry off the tip with a Kim 
wipe. 
15. Sonicate the 35 ml of cell solution for four minutes. Clean the sonicator after each use with 
ddH2O for two minutes. Repeat two more times (three times total). 
16. Transfer the sonicated cells to two polycarbonate tubes. Make sure each tube has the same 
volume with less than 0.2 g difference. Use a scale to determine the mass. 
17. Spin the polycarbonate tubes using the centrifuge in -80°C for 20 minutes at 15,000 x g (angular 
velocity between 10,000 – 10,500 rpm) at 4°C. 
18. Collect supernatant in a 50 ml conical and discard the pellet. The PLD is in your supernatant. 
Keep the PLD supernatant on ice, but do not freeze! 
B. Purifying PLD with a Metal Affinity Column 
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1. Get a column from the cold room and a TALON® Superflow™ Metal Affinity Resin from the 
fridge. 
If the resin is not new, follow steps 2-9:  
2. Set up the column on a metal stand with a clamp. Put a medium-sized beaker underneath the 
column to collect waste. Let the sodium azide solution flow through. Wash the column three 
times with 8 ml of MES buffer. 
3. Wash the resin once with 8 ml of binding buffer. Cap the column and add binding buffer, 
resuspending and transfer to 50 mL conical tube.  
4. Spin in the TC room at 1800 rpm for 1 minute at 4°C. Discard supernatant. 
5. Add another 8 ml of binding buffer and repeat step 4. 
6. Add the PLD supernatant and shake gently for 20 minutes in the cold room. Make sure the 
shaker is set up in the cold room. Repeat step 4. 
7. Add 8 ml binding buffer to PLD + resin. Shake gently at 4°C for 10 minutes. Repeat step 4. 
8. Add 8 ml of binding buffer and transfer back to the column. Discard flow through. 
9. Wash again with 8 ml of binding buffer. Discard flow through. 
10. Soak with 10 mM imidazole wash buffer for 8 minutes. Discard flow through. Repeat two more 
times (three times total). 
11. Cap column. Add 2 ml of 300 mM elution buffer and soak for 15 minutes. Collect PLD flow 
through in a 2 ml freezing vial. 
12. Rinse the resin with 8 ml of MES buffer. Cap the column and fill with sodium azide solution. 
Store resin at 4°C. 
13. Continue PLD purification (recommended), but the PLD can be frozen at this point in the -20°C 
freezer. 
 
 
 
Formalin-Inactivation  
 
MATERIAL: 
10% buffered formalin: 
10ml 37% formaldehyde 
90ml distilled water 
 
1.20g Na2HPO4 (anhydrous) 
0.30g KH2PO4 (anhydrous) 
5 ml 37% formaldehyde 
45 ml distilled water 
0.60 g Na2HPO4 (anhydrous) 
0.15 g KH2PO4 (anhydrous) 
 
METHOD: 
 
1. For every 1ml of toxin solution (concentration 1-
concentration of 0.4%) 
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2. Incubate at 37oC for 72 hours with gentle agitation (on the rocker). 
3. Dialyze the toxoid against 3 changes of PBS (at least 2 liters, 4 liters is better) overnight at 4oC. We 
use 14,000 molecular weight cutoff dialysis tubing.  If multiple samples are being dialyzed 
together, do 4 to 5 changes of PBS.  
4. Test by a protein assay such as BCA.  Much of the protein may precipitate out, so be sure to 
resuspend well and note whether you observe an obvious precipitate.  
 
BCA Assay 
Standards  
Vial Volume of Diluent 
(1X PBS) 
Volume of BSA Final BSA 
Concentration 
A  0 µL 200 µL 2000 µg/ml 
B 100 µL 100 µL  1000µg/ml 
C 100 µL 100 µL of B 500µg/ml 
D 100 µL 100 µL of C 250 µg/ml 
E 100 µL 100 µL of D 125 µg/ml 
F 100 µL 100 µL of E 62.5 µg/ml 
G 100 µL 100 µL of F 31.25 µg/ml 
H 100 µL 0 µL  0 µg/ml 
 
Working Reagent (WR)  
(# of Standards + # of unknowns) x (# of replicates) x ( volume of WR added per sample) = Total volume 
of WR needed 
WR Recipe 
50 parts of BCA Reagent A with 1 part Reagent B (50:1). Mix until a clear green WR develops 
Protocol  
(1) Add 25 µL of each standard and unknown to the wells. I tested each sample in triplicates (So make 
sure you have at least 75 µL of each standard and unknown.  
(2) Add 200 µL of WR to each sample well. 
(3) Mixed plate for ~30 seconds 
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(4) Cover plate and incubate for 30 mins @ 37°C  
(5) Cool plate to RT 
(6) Measure OD570 
Plate Reader Settings 
M = 4:570 (single) 
Mixing = ON (30 seconds) 
Incubation = ON (37°C) 
 
Western Blot 
Notes:  
(1)  Use premade gel (ie BioRad 4-15% gradient TGX Ready Gels) 
(2)  Start heating block to 94 C while you are setting up apparatus 
1. Remove green tape along the bottom of the gel 
2. Put gel on gel stand, shorter plate facing in and making a snug fit just below the gasket pads (see 
figure 1) 
3. Put other gel or dam on opposite side of apparatus in the same manner 
 
If using older Biochem Department apparatus: 
4. The clamp apparatus flaps should be open.  Holding gels to stand, insert the gel stand into the top of 
the clamp apparatus.  Be sure to push down firmly as you slide it into place so it is all the way at the 
bottom of the clamp apparatus 
5. While pushing downward, clamp the gel into place by closing the flaps on the gel clamp.   
6. Lower the clamp apparatus into the electrophoresis tank. 
 
If using Tetra-cell: 
4. Make sure to put the gel stand with banana plugs in the proper tank slot so that the lid to the tank 
will fit onto the electrodes.   
5. Gel stand has “butterfly” clamps that fold up to lock the plates in place.  May need to start raising 
them slightly before plates will sit perfectly.   
6. Lower clamped gel stand into electrophoresis tank 
7. Fill the top chamber in between the plates with running buffer (buffer level must be higher than the 
top of the wells).  Fill the bottom of the chamber past where the clamp apparatus wire with running 
buffer.  
8. Remove comb 
9. With a transfer pipet, flush the wells with running buffer.   
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Samples:  
1. Add -mercaptoethanol to the appropriate amount of 1X loading dye: 5% (50 ul -mercaptoethanol 
to 950 ul dye. 
2. Put cap holders on tube lids if desired.  Boil samples for 3-5 minutes. Markers we use do not need to 
be boiled. 
3. Quick spin samples 
4. Load 10 ul of marker per lane and up to 25 ul of each sample per lane.   
 
Running gel 
1. Put top on electrophoresis tank matching the red lead to the red electrode and the black lead to the 
black electrode. 
2. Run at 100V for 1 – 1.5 hrs.  Protein will run toward the positive electrode 
  
After gel has run: 
1. Turn off power supply and remove electrophoresis tank lid 
2. Pour off buffer from upper chamber 
3. Remove the clamp apparatus.  Open the flaps 
4. Pull the gel stand up out of the clamp apparatus.  Be sure to keep a finger holding each gel so they 
don’t fall off stand 
5. Take gels off the gel stand.   
6. Insert the BioRad opening lever between the plates at one of the arrows marked on the gel plates 
and gently pry plates appart.  Repeat at each of the other three arrows (one in each corner)  
7. Now that the plates have been loosened, use the lever to fully pry them apart, so that the gel stays 
on one of the plates. 
 
For Coomassie staining a gel:   
1. Put plate with gel into a container of H2O.  Float gel off the plate 
2. Wash gel 3 times in ddH2O for 5 min. each with shaking.   
3. Stain gel in Bio-Safe Coomassie Stain for at least 1 hr with shaking 
4. Wash gel one time in ddH2O for 5 min, then in ddH2O for at least 1 hr. 
5. Photograph stained gel 
 
For Western Blotting a gel 
1. Soak gel for 30 min in room temp transfer buffer to equilibrate (so gel doesn’t shrink during 
transfer) 
2. Prepare nitrocellulose membrane: wet slowly in distilled water (with one edge at a 45 angle, slowly 
dip corner into water and slowly lower the membrane in until membrane is completely wet. Then 
equilibrate for 10-15 min in transfer buffer 
3. Put transfer cassette in large pyrex pan.  Black side of open cassette should be flat against the 
bottom of the pan. Assemble blot sandwich on top of black side. 
4. Put soaked pad on the black side.  Pour enough transfer buffer into the pyrex pan to keep pad moist 
but keep liquid level below the top of the pad (so subsequent layers don’t float!) 
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5. Assemble the rest of sandwich.  Make sure everything is soaked with transfer buffer.  Whatmann 
paper and membrane should be cut to the size of the gel. Keep everything wet with buffer and roll 
with pipet or conical to remove any air bubbles each time you add a layer!  
            Order: 
a. Soaked sponge 
b. 1 piece Whatmann paper.  Use this piece of Whatmann paper to slide under the gel to move 
it to cassette 
c. Gel 
d. membrane 
e. 1 piece Whatmann paper 
f. Soaked sponge 
6. Close sandwich tightly.  Insert into transfer apparatus with black side of cassette against black side 
of apparatus. Add transfer buffer to apparatus until the cassette is completely covered. 
7. Transfer at 20 V for 12 hours (or 12V O/N) in the cold room on top of stir plate.  Have stir bar in 
apparatus below the transfer cassette (stir bar may not be able to turn in a full circle but will keep 
buffer moving).  Should be small stream of bubbles visible on the black side of the apparatus (may 
have to turn up voltage temporarily to see the bubbles).  
8. Make blocking buffer (so you are sure milk is fully dissolved by the next day).  
9. After transfer is complete, open transfer cassette in pyrex pan. 
a. Mark wells on membrane with pencil.  Cut corner to orient if needed. 
b.   Rinse membrane in ddH2O 
10. Block membrane in blocking buffer for 1 hour at room temperature (or O/N at 4C) with rocking. 
Volume for petri dish = ~ 8 ml.  Remove blocking buffer. 5 min. wash is optional 
11. Add primary antibody diluted in blocking buffer (usually sera dilution is 1:1500).  Incubate for 1 hour 
with rocking. 
12. Wash membrane in wash buffer (TBST).  Wash 3-4 times for 10-15 minutes each. 
13. Change tray if desired.  Add secondary antibody (usually anti-IgG) diluted in blocking buffer (usually 
1:1500 dilution). Incubate for 1 hour at room temperature with rocking. 
14. Wash 2 times in TBST for 10-15 minutes each.   
15. Wash once in TBS (no tween! Tween inhibits the Opti 4-CN reaction) for 10-15 min. 
16. Add the Opti-4CN Substrate to Opti 4-CN diluent (per 10 ml: 1mL of Opti-4CN Diluent + 9 mL ddH20 + 
0.2 mL of Opti-4CN Substrate). Mix Well. Pour onto membrane. Incubate with gentle agitation until 
desired signal level is reached. 
17. Rinse w/ dd H20 and photograph  
 
5X SDS Electrophoresis buffer 
15.1 g Tris base (final concentration in 5x = 0.125 M) 
72.0 g glycine (final concentration in 5x = 0.96 M) 
5.0 g SDS (final concentration in 5x = 0.5% 
H2O to 1000 ml 
Adjust pH to 8.3 only after diluting to 1x 
Store at 4C (for up to a month) 
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10X Transfer Buffer (1L) 
30.25 g Tris base 
144.2 g glycine 
ddH2O to 1000 ml 
pH will be around  8.3 – 8.4  
Note: pH reads at ~8.7 at first.  Takes a few ml of concentrated HCl (~ 6.5 ml) to pH to 8.4 
 
1X Transfer Buffer (4 L) 
400 ml 10X Transfer Buffer 
800 ml methanol 
ddH2O to 4 L 
 
Tris-Buffered Saline (TBS):  1L 
12.1 g Tris base (100 mM) 
800 ml ddH2O 
pH to 7.5 with HCl  
Note: adjust pH at the temperature that you plan to use the solution. 
Takes a few ml (~6.75 ml) of concentrated HCl to pH to 7.5 
Then add… 
8.8 g NaCl (150 mM or ~0.9%) 
ddH2O to 1000 ml 
 
Wash buffer (TBST: Tris-Buffered Saline + Tween) 
TBS + 0.1% Tween 20 
Can be stored several months at 4C 
 
Blocking Buffer 
5% nonfat dry milk in TBST 
 
 
QIAprep Miniprep for E. coli Plasmid Isolation – Protocol 
 
1.  Grow E. coli colonies on an LB agar + AMP plate overnight at 37°C. 
2.  Once colonies look healthy, pick a single colony from a freshly-streaked selective plate and inoculate 
a culture in 5mL LB medium containing AMP.  Incubate 12-16 hours at 37°C with vigorous shaking. 
3.  Aliquot bacteria into 2- or 1- mL microcentrifuge tubes.  Harvest the bacteria cell by centrifuging at 
13,000 rpm for 3 min at RT. 
4.  Resuspend the bacteria pellet in 250 uL Buffer P1 and transfer to a microcentrifuge tube. 
5.  Add 250 uL Buffer P2 and mix thoroughly by inverting the tube 4-6 times. 
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6.  Add 350 uL Buffer N3 and mix immediately and thoroughly by inverting the tube 4-6 times. 
7.  Centrifuge for 10 min at 13,000 rpm in a microcentrifuge. 
8.  Apply the supernatant from Step 7 to the QIAprep spin column by decanting or pipeting. 
9.  Centrifuge for 30-60 sec and discard the flow-through. 
10.  Wash the QIAprep spin column by adding 0.5 mL Buffer PB and centrifuging for 30-60 sec. Discard 
the flow-through. 
11.  Wash QIAprep spin column by adding 0.75 mL Buffer PE and centrifuging for 30-60 sec.  Discard 
flow-through, and centrifuge for an additional 1 min to remove residual wash buffer. 
12.  To elute DNA, place the QIAprep column in a clean 1.5 mL microcentrifuge tube.  Add 50 uL Buffer 
EB or water to the center of each QIAprep spin column, let stand 1 min, and centrifuge for 1 min.   
13.  Store in -20°C. 
 
Restriction Mapping (Current Protocols in MoBio, Vol 1, 3.2.1) 
Definition: To construct a map of specific sites where restriction endonucleases cleave DNA  
 
Purpose: To generate a restriction map, aid in nucleotide sequence analysis, subclone, and/or confirm 
the identity of an isolated plasmid 
 
How: The DNA is cleaved at or near specific nucleotide sequences with restriction endonucleases, and 
determination of the sizes of the resulting DNA fragments is done via agarose or acrylamide gel 
electrophoresis. 
 
Parameters: Can be done with a variety of restriction enzymes individually or in combo 
         Cloned DNA segments up to 20kb in length 
         Use restriction enzymes that cleave the DNA relatively infrequently 
Materials 
 DNA sample in TE buffer on ice 
Restriction endonucleases (EcoR1, Pvu1) 
  EcoR1: G/AATTC, 37°C rxn, 65°C inact 
  Pvu1:  CGAT/CG, 37°C rxn, 100°C inact 
 10x restriction endonuclease buffers  (EcoRI and PvuI use the same buffer) 
 10x loading buffer 
 
1.  Pipette the following into a microcentrifuge tube IN THE FOLLOWING ORDER: 
 20uL reaction 50uL reaction 
ddH2O 8.0 uL 33.0 uL 
10X restriction buffer 2.0 uL 5.0 uL 
DNA (127ug/mL) 8.0 uL 8.0 uL 
Restriction endonuclease 2.0 uL 4.0 uL 
 
NOTE: The volume of restriction endonuclease added should be less than 1/10 the volume of the final 
reaction mixture.  
 
2.  After adding the restriction endonuclease, incubate the mixture overnight at 37°C. 
NOTE: Since the reaction temperatures of the restriction endonucleases are the same, they can be added 
simultaneously and incubated at 37°C.  
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3.  Immediately before loading a gel, stop the reaction by adding 4uL or 10uL (20% of rxn volume) of 10X 
loading buffer. 
 
 
Agarose Gel Electrophoresis 
Purpose: To separate, identify, and purify 0.5-25. kb DNA fragments 
 
How: Prepare an agarose gel w/ concentration appropriate for size of DNA fragments to be separated; 
run gel; and stain gel or illuminate with UV light if ethidium bromide is incorporated 
 
Materials 
 Electrophoresis buffer (0.5X TBE or 1X TAE) 
 Ethidium bromide solution 
 Electrophoresis-grade agarose 
 10X loading buffer (provided by Hector) 
 DNA molecular weight markers 
  
 55°C water bath 
 Horizontal gel electrophoresis apparatus 
 Gel casting platform 
 Gel combs 
 DC power supply 
 
Preparing the gel 
WEAR GLOVES.  ETHIDIUM BROMIDE IS A CARCINOGEN! 
1.  Prepare 600mL of electrophoresis buffer to fill the electrophoresis tank. Add 600uL of stock ethidium 
bromide solution (0.5mg/mL) for a final concentration of 0.5ug/mL. 
NOTE: Make sure the concentration of ethidium bromide in the gel is identical to the concentration in the 
buffer. 
 
2.  Add 1.0g of electrophoresis-grade agarose to a 100mL volume of electrophoresis buffer for 
constructing a 1% agarose gel.   
NOTE: A 1% agarose gel has an effective range of resolution of linear DNA fragments listed as 10 to 0.5 
kb.  Gels typically contain 0.8-1.5% agarose. 
 
3.  Melt the agarose in a bottle with the cap loosely on in a microwave oven and swirl to ensure even 
mixing.  You can also autoclave it in an Erlenmeyer flask with a foil lid taped on.  Only fill the flask half-
full. 
 
4.  Seal the gel-casting platform with tape.  Once the agarose has cooled so that you can touch your 
hand to the bottom of the bottle or flask (very warm, not hot), add 100uL of stock ethidium bromide 
solution.  Pour in the melted agarose and insert the gel comb, making sure that no bubbles are trapped 
underneath the comb and all bubbles on the surface of the agarose are removed before the gel sets. 
 
Loading and running the gel 
5.  After the gel has hardened, remove the tape from the open ends of the gel platform and withdraw 
the gel comb, taking care not to tear the sample wells. 
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NOTE: Low percentage gels and gels made from low gelling/melting temperature agarose should be 
cooled in 4°C to gain extra rigidity and prevent tearing. 
6. Place the gel-casting platform containing the set gel in the electrophoresis tank.  Add sufficient 
electrophoresis buffer to cover the gel to a depth of about 1 mm.  Make sure no air pockets are 
trapped within the wells.   
 
7. Prepare the DNA sample by adding the appropriate amount of 10X loading buffer—20% of reaction 
volume. Load each well with 20uL sample.  Include the appropriate DNA molecular weight markers.   
 
8.  Run the gel at 100V for ~1.8 hours.  Make sure the leads are attached such that the DNA will 
migrate toward the positive lead (red).  Usually you will run the gel until the bromophenol blue dye 
is 2/3 of the way down the gel and the xylene cyanol is 1/3 of the way.   
Note: If you are using pre-made loading buffer, it might have different dyes, so check the directions. 
 
9. Turn off the power supply when the fragments have migrated sufficiently.  Photograph the gel. 
 
 
 
 
 
 
 
 
 
